Physician profile
Amitha Gona
NPI 1053611566
$3,305.58
in general payments reported to CMS, 2019-2025
23 companies · $720 in 2025
The $720 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $128 · 2022: $27.58 · 2023: $1,635 · 2024: $452 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547 · Consulting Fee: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.01 |
| Consulting Fee | $1,260.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,540.07 | 2019-2025 | Tremfya |
| Amgen INC. | $617.31 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $383.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $181.46 | 2019-2025 | |
| Genzyme Corporation | $70.36 | 2023-2025 | |
| Celgene Corporation | $64.24 | 2024-2025 | Orencia |
| Horizon Therapeutics Plc | $50.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.16 | 2024 | Cyltezo |
| Organon LLC | $42.87 | 2023-2025 | Hadlima |
| Shionogi INC | $34.15 | 2025 | Fetroja |
| E.R. Squibb & Sons, L.L.C. | $32.62 | 2019 | |
| Radius Health, INC. | $30.62 | 2023 | |
| Sandoz INC. | $27.04 | 2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $23.36 | 2025 | Strensiq |
| Fresenius Kabi USA, LLC | $23.33 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.85 | 2024 | Saphnelo |
| Octapharma USA, INC. | $18.92 | 2023 | Panzyga |
| Otsuka America Pharmaceutical, INC. | $17.56 | 2025 | Jynarque |
| Melinta Therapeutics, LLC | $16.70 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Glaxosmithkline, LLC. | $14.93 | 2025 | Benlysta |
| Ucb, INC. | $14.66 | 2025 | Bimzelx |
| Antares Pharma, INC. | $14.44 | 2019 | |
| Pfizer INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitha Gona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.